The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Selina M. Luger, University of Pennsylvania, Philadelphia, US. We asked: What are the current challenges in ALL that need to be addressed?
What are the current challenges in ALL that need to be addressed?
Here, she highlights a number of considerations regarding ALL treatment strategies:
1) Should all patients receive transplant for the treatment of ALL?
2) Do all patients with Philadelphia chromosome-positive ALL require intensive chemotherapy?
3) Are there patients with Philadelphia chromosome-negative ALL who demonstrate good responses without chemotherapy?
4) Should targeted agents be incorporated into chemotherapy regimens?
Selina M. Luger concludes by highlighting the lack of targeted agents available for T-cell ALL and outlines emerging therapeutics in this setting.